What happens when a cancer drug works exactly as designed — stops the tumor for months — but the patient dies sooner? That paradox runs through the biggest oncology dataweekend of the year.
We distill the data drop from the World Conference on Lung Cancer (WCLC) in Seoul: Ivonescimab beating Keytruda head-to-head in first-line non-small cell lung cancer, theDESTINY-Lung04 survival paradox, two same-day breakthroughs that revived smallcell lung cancer after decades of stagnation, and what the wave of genericsmeans for the oncology "blockbuster."
We cut through the jargon on bispecific antibodies, antibody-drug conjugates, and BiTEs — and why sequencing may now matter as much as the drug itself.
Disclaimer:AI-generated from publicly available news. Not medical or investment advice.May contain errors — verify against primary sources.
00:00 The Survival Paradox
00:32 Welcome to the Deep Dive
01:19 HARMONI-2: Ivonescimab vs Keytruda
02:25 How Bispecific Antibodies Work
03:13 The Survival Numbers
04:18 The Single-Region Trial Caveat
05:18 Merck's Response
06:04 DESTINY-Lung04: The Paradox
06:40 How Antibody-Drug Conjugates Work
08:10 Why the Survival Paradox Happens
09:29 A Curveball: Sevabretinib
11:10 RESILIENT-3: Cullinan vs J&J
14:37 Small Cell: The Graveyard Awakens
16:12 Amgen's BiTE: Molecular Handcuffs
17:09 Sequencing, Not Competing
18:08 Diagnostics & Disease Interception
19:38 Where the Venture Capital Flows
20:22 The Generics Reality Check
21:07 The End of the Blockbuster Era?
